Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 2Endocrine 2Thoracic 1Genitourinary 1CNS 1Breast 1

Conditions

Breast Neoplasms 8Neoplasm Metastasis 2Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Prostatic Neoplasms 1Lung Neoplasms 1Head and Neck Neoplasms 1Esthesioneuroblastoma, Olfactory 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Medullary 1Breast Neoplasms, Male 1Advanced Breast Cancer 1Adenocarcinoma, Follicular 1

Interventions

selpercatinib 3Trastuzumab 2vandetanib 1tipifarnib 1entrectinib 1alectinib 1Ritonavir 1Radiotherapy 1Paclitaxel 1Interleukin-12 Subunit p35 1Interleukin-12 1Indinavir 1Docetaxel 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid Cancer, Papillary × vandetanib × Breast × Clear all
NCT00937417 2017-04-24

S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors

SWOG Cancer Research Network

Phase 1 Withdrawn
BreastCNSEndocrineGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Thyroid Cancer, Papillary, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Lung Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary, Esthesioneuroblastoma, Olfactory, Breast Neoplasms, Male, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡